Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

Related Articles by Review for PubMed (Select 23349632)

1.

The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes.

Tavis JE, Cheng X, Hu Y, Totten M, Cao F, Michailidis E, Aurora R, Meyers MJ, Jacobsen EJ, Parniak MA, Sarafianos SG.

PLoS Pathog. 2013 Jan;9(1):e1003125. doi: 10.1371/journal.ppat.1003125. Epub 2013 Jan 22.

2.

The hepatitis B virus ribonuclease H as a drug target.

Tavis JE, Lomonosova E.

Antiviral Res. 2015 Jun;118:132-138. doi: 10.1016/j.antiviral.2015.04.002. Epub 2015 Apr 8. Review.

PMID:
25862291
3.

Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.

Delaney WE 4th, Locarnini S, Shaw T.

Antivir Chem Chemother. 2001 Jan;12(1):1-35. Review.

PMID:
11437320
4.

Treatment of chronic hepatitis B virus infection - Dutch national guidelines.

Buster EH, van Erpecum KJ, Schalm SW, Zaaijer HL, Brouwer JT, Gelderblom HC, de Knegt RJ, Minke Bakker C, Reesink HW, Janssen HL; Netherlands Association of Gastroenterologists and Hepatologists.

Neth J Med. 2008 Jul-Aug;66(7):292-306. Review.

5.

On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.

Chien RN.

J Gastroenterol Hepatol. 2010 May;25(5):852-7. doi: 10.1111/j.1440-1746.2010.06271.x. Review.

PMID:
20546437
6.

Molecular mechanisms of resistance to antiviral therapy in patients with chronic hepatitis B.

Yuan HJ, Lee WM.

Curr Mol Med. 2007 Mar;7(2):185-97. Review.

PMID:
17346170
7.

Inhibitors of HIV-1 reverse transcriptase and integrase: classical and emerging therapeutical approaches.

Tarrago-Litvak L, Andreola ML, Fournier M, Nevinsky GA, Parissi V, de Soultrait VR, Litvak S.

Curr Pharm Des. 2002;8(8):595-614. Review.

PMID:
11945161
8.

Perspectives for the treatment of hepatitis B virus infections.

De Clercq E.

Int J Antimicrob Agents. 1999 Jul;12(2):81-95. Review.

PMID:
10418752
9.

HIV-1 integrase and RNase H activities as therapeutic targets.

Andréola ML, De Soultrait VR, Fournier M, Parissi V, Desjobert C, Litvak S.

Expert Opin Ther Targets. 2002 Aug;6(4):433-46. Review.

PMID:
12223059
10.

Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success.

Chien RN, Liaw YF.

Best Pract Res Clin Gastroenterol. 2008;22(6):1081-92. doi: 10.1016/j.bpg.2008.11.003. Review.

PMID:
19187868
11.

The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta-analysis.

Yu S, Jianqin H, Wei W, Jianrong H, Yida Y, Jifang S, Liang Y, Zhi C, Hongyu J.

Ann Hepatol. 2013 May-Jun;12(3):364-72. Review.

PMID:
23619252
12.

Hepatitis B virus: from diagnosis to treatment.

Dény P, Zoulim F.

Pathol Biol (Paris). 2010 Aug;58(4):245-53. doi: 10.1016/j.patbio.2010.05.002. Epub 2010 Jul 1. Review.

PMID:
20580167
13.

Drug resistance in antiviral therapy.

Locarnini S, Bowden S.

Clin Liver Dis. 2010 Aug;14(3):439-59. doi: 10.1016/j.cld.2010.05.004. Review.

PMID:
20638024
14.

HIV-1 integration as a target for antiretroviral therapy: a review.

Pluymers W, De Clercq E, Debyser Z.

Curr Drug Targets Infect Disord. 2001 Aug;1(2):133-49. Review.

PMID:
12455410
15.
16.

Design and evaluation of hepatitis B virus inhibitors.

Hantz O, Kraus JL, Zoulim F.

Curr Pharm Des. 2000 Mar;6(5):503-23. Review.

PMID:
10788594
17.

Antiviral therapy targeting viral polymerase.

Tsai CH, Lee PY, Stollar V, Li ML.

Curr Pharm Des. 2006;12(11):1339-55. Review.

PMID:
16611119
18.

Emerging pipeline drugs for hepatitis B infection.

Cox N, Tillmann H.

Expert Opin Emerg Drugs. 2011 Dec;16(4):713-29. doi: 10.1517/14728214.2011.646260. Review.

PMID:
22195605
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk